Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
|Slideshows|August 23, 2018
Psychiatry Rounds: Workplace Mental Health and More
Author(s)Laurie Martin
The perils of job insecurity; depression and cardiac risks; the longest-running mental health study; smart drugs that aren’t so smart; heatstroke in psychiatric patients; an autism puzzler; and psychosis and eating disorders.
Advertisement
Advertisement
Related to this article
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
Schizophrenia: A Telltale of the Brain’s Complexity
4
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
5